A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects

• Published in: Cancer chemotherapy and pharmacology Vol. 87; no. 3; pp. 349 - 359
• Main Authors: Zhu, X., Ding, Y., Yu, Y., Wang, M., Zhou, W., Wang, J., Zhang, H., Chai, K., Zhang, X., Luk, A., Jiang, W., Liu, S., Zhang, Q.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2021; Springer Nature B.V
• Subjects: Adverse events; Bioequivalence; Breast cancer; Cancer Research; Clinical trials; Immunogenicity; Immunotherapy; Intravenous administration; Medicine; Medicine & Public Health; Monoclonal antibodies; Oncology; Original Article; Pharmacokinetics; Pharmacology/Toxicology; Safety; Targeted cancer therapy; Trastuzumab; China; Tastuzumab; Breast cancer; Bioequivalence; Pharmacokinetics; Biosimilar
• ISSN: 0344-5704; 1432-0843; 1432-0843
• DOI: 10.1007/s00280-020-04196-9

Purpose This study evaluated the bioequivalence of China-manufactured biosimilar, HLX02, to reference China (CN)- and European Union (EU)-sourced trastuzumab. Methods This was a two-part Phase 1 study conducted in healthy Chinese males. Part 1 evaluated the safety of different doses of HLX02 (2, 4, 6 or 8 mg/kg; intravenous infusion over 90 min, n  = 3 per group). Part 2, a randomized, double-blind study, investigated the pharmacokinetics (PK), safety and immunogenicity of study drugs (HLX02 [ n  = 37], CN-trastuzumab [ n  = 35] or EU-trastuzumab [ n  = 37] at the dose suggested by Part 1 results). The primary PK endpoint was the area under the serum concentration–time curve from time 0 to infinity (AUC inf ). Equivalence was concluded if the 90% confidence interval (CI) for the geometric least squares mean ratio (GLSMR) fell in the equivalence criteria of 0.80–1.25. Results In Part 1, all doses of HLX02 were well tolerated and 6 mg/kg was suggested for Part 2. The GLSMRs and 90% CIs for AUC inf were: 0.950 (0.891–1.013), 0.914 (0.858–0.973) and 0.962 (0.902–1.025) for HLX02 versus CN-trastuzumab, HLX02 versus EU-trastuzumab and CN-trastuzumab versus EU-trastuzumab, respectively. Secondary endpoints comparisons also fell in the equivalence criteria. Treatment-emergent adverse events were reported in 75.7, 86.5 and 70.3% of the subjects in HLX02, CN-trastuzumab, and EU-trastuzumab groups, respectively. No serious adverse events or deaths occurred. No treatment-related anti-drug antibodies were detected. Conclusion This study demonstrated comparable safety profiles and PK bioequivalence among HLX02, CN-trastuzumab and EU-trastuzumab in healthy Chinese male subjects. Clinical trial registration ClinicalTrials.gov, NCT02581748, registered at October 19, 2015.